Epi-immunotherapy for cancers:rationales of epi-drugs in combination with immunotherapy and advances in clinical trials  

作　　者：Yang Xu Ping Li Yang Liu Dijia Xin Wen Lei Aibin Liang Weidong Han Wenbin Qian 

机构地区：[1]Department of Hematology,the Second Affiliated Hospital,College of Medicine,Zhejiang University,Hangzhou,Zhejiang 310009,P.R.China [2]Zhejiang Provincial Key Laboratory for Cancer Molecular Cell Biology,Life Sciences Institute,Zhejiang University,Hangzhou,Zhejiang 310058,P.R.China [3]Department of Hematology,Tongji Hospital of Tongji University,Shanghai 200065,P.R.China [4]Department of Bio-Therapeutic,the First Medical Centre,Chinese PLA General Hospital,Beijing 100853,P.R.China

出　　处：《Cancer Communications》2022年第6期493-516,共24页癌症通讯（英文）

基　　金：the National Natural Science Foundation of China,Grant/Award Numbers:81830006,82170219,81830004,81800188;the Science Technology Department of Zhejiang Province,Grant/Award Number:2021C03117;the Natural Science Foundation of Zhejiang Province of China,Grant/Award Number:LY21H080005。

摘　　要：Over the last two decades,several epi-drugs,immune checkpoint inhibitors(ICIs)and adoptive cell therapies have received clinical approval for use in certain types of cancer.However,monotherapy with epi-drugs or ICIs has shown limited efficacy in most cancer patients.Epigenetic agents have been shown to regulate the crosstalk between the tumor and host immunity to alleviate immune evasion,suggesting that epi-drugs can potentially synergize with immunotherapy.In this review,we discuss recent insights into the rationales of incorporating epigenetic therapy into immunotherapy,called epi-immunotherapy,and focus on an update of current clinical trials in both hematological and solid malignancies.Furthermore,we outline the future challenges and strategies in the field of cancer epi-immunotherapy.

关 键 词：chimeric antigen receptor T cell clinical trial DNA methylation Epi-drug Epiimmunotherapy histone acetylation immune checkpoint.tumor microenvironment vaccine 

分 类 号：R73[医药卫生—肿瘤]